Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $24.3750.

A number of research analysts have recently commented on XNCR shares. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price target (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Finally, Barclays lifted their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, February 26th.

Insider Activity at Xencor

In other news, VP John R. Desjarlais sold 4,118 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $46,327.50. Following the transaction, the vice president directly owned 266,333 shares in the company, valued at $2,996,246.25. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bassil I. Dahiyat sold 14,870 shares of Xencor stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total value of $167,287.50. Following the completion of the transaction, the chief executive officer directly owned 552,922 shares in the company, valued at $6,220,372.50. This represents a 2.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 44,020 shares of company stock worth $499,817. 4.76% of the stock is owned by insiders.

Institutional Trading of Xencor

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Walleye Capital LLC purchased a new stake in Xencor during the second quarter worth approximately $1,955,000. Squarepoint Ops LLC raised its stake in shares of Xencor by 3,150.0% in the 2nd quarter. Squarepoint Ops LLC now owns 363,153 shares of the biopharmaceutical company’s stock valued at $2,854,000 after acquiring an additional 351,979 shares during the period. SG Americas Securities LLC acquired a new position in shares of Xencor during the 3rd quarter valued at $1,062,000. Primecap Management Co. CA boosted its position in Xencor by 1.4% during the 3rd quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after purchasing an additional 147,700 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new stake in Xencor during the 3rd quarter worth $1,173,000.

Xencor Stock Performance

Shares of Xencor stock opened at $12.81 on Friday. Xencor has a fifty-two week low of $6.92 and a fifty-two week high of $18.69. The business’s fifty day moving average is $12.01 and its two-hundred day moving average is $13.46. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12. The firm has a market cap of $939.49 million, a PE ratio of -10.33 and a beta of 0.99.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. During the same period in the prior year, the firm posted ($0.62) earnings per share. The business’s quarterly revenue was down 46.6% compared to the same quarter last year. Analysts anticipate that Xencor will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.